Hugel Achieved Record-High Revenue and Operating Profit
Hugel delivered 2022 revenue of KRW281.7bn, operating profit of KRW102.5bn, up 21.5% YoY and 7.2% YoY, respectively Botulinum toxin's sales soared by 28.9% YoY; European sales in full swing Hugel aims to obtain marketing approval and launch products in the U.S. within this year SEOUL, South Korea, Feb. 9, 2023 /PRNewswire/...
Angel Yeast Announces Plans to Beef up Supply and Innovation Capabilities In Response to Increasing Global Yeast Demand
YICHANG, China, Feb. 20, 2023 /PRNewswire/ -- The rising demand for yeast-based products over the past few years heralds steady growth of the market in the future, which also poses new challenges that require manufacturers to catalyze innovation and ramp up production and technology development to meet the evolving needs of their customers....
Lepu Biopharma and Keymed Jointly Announces Global Exclusive Licence Agreement with AstraZeneca for CMG901
HONG KONG, Feb. 22, 2023 /PRNewswire/ -- Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) and Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) today jointly announces a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC). Under the licence agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialisation of...
MSCI ESG Updated I-Mab to “A” Rating
GAITHERSBURG, MD. and SHANGHAI, March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that I-Mab has been granted "A" rating by MSCI (Morgan Stanley Capital International) ESG, following MSCIESG's most recent annual review, and such...
HanAll Biopharma Reports First Quarter Results and Provides Business Update
Financial results for the first quarter ended with revenue of KRW 28.8 billion, up by 20 percent compared to the same period in 2022 HanAll made a strong start to 2023 with positive Phase 3 study results of anti-FcRn asset batoclimab for the treatment of generalized myasthenia gravis in China, setting...
CMUH Smart Medicine System Assisted the ARDS Specialist Team Successfully Reversed the Patient’s Critical Condition
TAICHUNG,Taiwan, May 15, 2023 /PRNewswire/ -- After the worldwide COVID-19 pandemic, most people suffered from mild disease, and "Acute Respiratory Distress Syndrome (ARDS)" is common for those critical COVID-19 patients. The 46-year-old of Ms. Chang, who had hypertension and nephropathy, accepted kidney transplantation surgery 10 years ago. She was tested positive for COVID-19 and had severe respiratory failure. Ms. Chang was...
CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.
SHANGHAI, May 18, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that CARsgen has initiated patient enrollment for Phase 2 of the clinical trial for CT041 in the U.S., for the treatment...
The 133rd Canton Fair Gathers Top Medical Equipment to Unlock the Health Code
GUANGZHOU, China, May 19, 2023 /PRNewswire/ -- Global healthcare takes center stage as the world recovers from the COVID-19 pandemic. As the public becomes more vigilant about their health, medical institutions are also stepping up their game in providing top-notch services and equipment. In the 133rd Canton Fair, over 700 companies showcased their latest offerings of home-use and professional medical...
Acepodia Secures $100 Million Series D Financing to Advance
First-In-Class Cell Therapies with Antibody-Cell Conjugation (ACC) Platform Series D led by Digital Mobile Venture with participation from additional existing investors Funds will support expansion and progress of oncology pipeline, including ACE1831 and ACE2016, antibody armed allogeneic gamma delta T-cell therapies ALAMEDA, Calif. and TAIPEI, June 6, 2023 /PRNewswire/ -- Acepodia, a clinical stage biotechnology company developing first-in-class...
Anti-Aging and Reproductive Medical Giants Gathered in Hong Kong Dragon’s Medical Led Chinese Medical Development
HONG KONG, June 9, 2023 /PRNewswire/ -- Dragon's Medical successfully held its Advance Medical Technology Press Conference 2023 at W Hong Kong today, signing strategic partnership agreements with various medical groups from Mainland China, Hong Kong and Taiwan, deepening their long-term strategic partnership. At the event, Dragon's Medical announced the launch of...
